Acuitas Scientists Co-Author Nature Article
Acuitas Therapeutics’ Chief Scientific Officer, Dr. Ying Tam, and Director of Formulation Development, Paulo Lin, co-authored (with several other scientists) a study titled “Molecular fate-mapping of serum antibody responses to repeat immunization” that was recently published in Nature. Please click
Acuitas Therapeutics Video Update
Acuitas Therapeutics is the global leader in the field of lipid nanotechnology. We specialize in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNP). We work with partners to develop new therapies to address unmet
Why I Work at Acuitas – Science & Social Fun
The third blog post in our series: “Why I Work at Acuitas” features Research Scientist, Reihaneh Hosseinzadeh. We recently caught up with Ms. Hosseinzadeh and she told us why she chose to work at Acuitas Therapeutics. From as far back as
Long COVID – What You Need to Know
As many countries (including Canada) shift into a post-pandemic environment, there are still important aspects to be aware of. The first is that there is still a risk of contracting COVID-19. People who are fully vaccinated can still get COVID-19.
Why I Work at Acuitas – A Project Manager’s Perspective
Today’s installment in our "Why I Work at Acuitas" series is with Acuitas’ Sr. Associate, Project Manager, Dr. Baishakhi Datta. We recently caught up with Dr. Datta and asked her a few questions about why she chose to work at
Why I Work at Acuitas – A New Series
This is the first post in our new series: "Why I Work at Acuitas." It will highlight some of the incredibly talented, intelligent and innovative people who work at Acuitas – and explain why they have chosen to be a
Acuitas Therapeutics Video Update
Acuitas Therapeutics is a global leader in the field of lipid nanotechnology. The team, led by President & CEO, Dr. Thomas Madden, is made up of a diverse group of highly experienced scientists and technical and administrative professionals – all
COVID-19 Vaccines and Children – an Important Conversation
Health Canada has approved the Pfizer/BioNTech COMIRNATY® mRNA vaccine for children ages five to 11. (This vaccine uses Acuitas Therapeutics’ lipid nanoparticle delivery system.) All vaccines approved for use in Canada undergo a strict testing, review and approval process. The Government
New Acuitas Therapeutics Video
Acuitas Therapeutics partners with pharmaceutical companies, biotechnology companies and academic institutes to advance nucleic acid therapeutics to the clinic and to the marketplace. After more than a decade of work on our lipid nanoparticle delivery system, it now plays a
What You Need to Know About COVID-19 Vaccines for Children
The Pfizer/BioNTech COVID-19 vaccine COMIRNATY® has received Health Canada’s approval for children ages five to 11. (Acuitas provides the lipid nanoparticle delivery system for this mRNA vaccine.) In a CBC article, which is in a useful Q&A format, a spokesperson for